Grants for Small businesses - Health

This funding opportunity provides support for high-risk clinical trials focused on infectious, immunologic, and allergic diseases, encouraging innovative research that can lead to new treatments and therapies.

This funding opportunity provides financial support to organizations that will establish training centers and support hubs to improve the skills and job flexibility of direct care workers in New York, addressing the growing demand for Personal Care Aides, Home Health Aides, and Certified Nursing Assistants.

This funding opportunity supports research projects aimed at reducing stigma related to HIV/AIDS in low- and middle-income countries, with a focus on improving health outcomes for affected populations.

This grant opportunity allows Skilled Nursing Facilities (SNFs), non-profit organizations, consumer advocacy organizations, and more to apply for funding to implement projects to improve the lives of SNF residents. Examples of projects include, but are not limited to, developing and implementing methods to increase Person-Centered Care, Infection Control Training, implementing technology to prevent resident falls, and more. Examples of projects that will not be approved for CMP funding include, but are not limited to, research-only projects, projects with an indirect benefit to nursing residents, capital improvements to a facility, duplication of CMS requirements, and paying for nursing home staff salaries. Applicants must use the template provided on the CDPH website. Projects may vary in length up to a maximum of 36 months. Award size is dependent on project scope and request and funding availability. There is no stated limit to the amount of funds an applicant can request. Keywords: Civil Money Penalty, CMP, CDPH, CMS, Skilled Nursing Facility, Reinvestment, Public Health, SNF

This funding opportunity provides $1 million to support a national coordinating center that will enhance collaboration, education, and research initiatives in nonmalignant hematology, targeting a diverse range of eligible institutions.

The Alliance for Pediatric Device Innovation (APDI) is offering grants up to $50,000 for pediatric medical devices aimed at improving the monitoring, diagnosis, or treatment of youth substance use disorders and addiction. Up to $150,000 in total grant funds are available for distribution. Eligible applicants include inventors from established businesses, startups, and academic researchers with commercializable device concepts that address unmet pediatric needs. The goal is to support the development of devices that can be commercialized, with an emphasis on bridging the gap between prototyping and FDA approval, marketing, and sales. Proposals should focus on innovations such as AI-based diagnostic tools, digital therapeutics, wearable devices, and neuromodulation therapies. The application deadline is July 30, 2024, and winners will be announced on August 15, 2024.

This funding opportunity supports community-driven research projects that assess environmental exposures and develop public health interventions to address health disparities in affected communities.

This funding opportunity provides financial support for institutions and organizations to create and manage a resource that supplies human tissues and organs for biomedical research, benefiting studies on various diseases and health conditions.

This funding opportunity provides financial support to small businesses and organizations developing innovative medical technologies and digital health solutions to improve health outcomes.

This funding opportunity provides financial support to states and organizations for developing a coordinated care model that improves health services for children with serious, long-term medical conditions.

This funding opportunity supports multidisciplinary research teams in the U.S. working on complex biomedical questions, with a focus on advancing foundational biological processes and addressing critical health issues.

This funding opportunity supports innovative interventions to improve the health and quality of life for people living with HIV, particularly those from racial and ethnic minority populations and low-income backgrounds, by addressing related health issues and promoting successful aging.

This grant provides funding to U.S. small businesses for research and development projects that aim to advance health-related technologies and facilitate their commercialization.

This funding opportunity provides financial support to small businesses with active Phase I SBIR or STTR grants from NIH or CDC, helping them accelerate the commercialization of biomedical and public health innovations through training and market research.

To establish a Data Center to coordinate and analyze single cell and other molecular data sets generated by Single Cell Opioid Responses in the Context of HIV (SCORCH) and other NIDA-funded HIV and substance use disorder projects and to make the data findable, accessible, interoperable, and reusable (FAIR) to enable secondary analyses by the scientific community. This is a non-competitive funding opportunity intended to fund a single award. The National Institute on Drug Abuse (NIDA) is announcing its intent to issue a single source cooperative agreement award to the University of Maryland Baltimore to 1. Coordinate all the data generated by the SCORCH consortium, 2. Analyze all the data generated by the SCORCH consortium, 3. Perform necessary SCORCH program scientific outreach activities, and 4. Support SCORCH consortium communication. The current SCORCH Data Center is integrated with the rest of the SCORCH consortium and is familiar with the current data, metadata, and data quality metric standards and data pipelines. They were involved in establishing these standards and have been/are working closely with key personnel on SCORCH data generation projects to ensure data and associated metadata are deposited. Continued support of the University of Maryland Baltimore SCORCH Data Center to complete the SCORCH Program activities will enable seamless SCORCH data coordination and archiving, will prevent disruption in data analysis, and will allow continued support of the currently existing SCORCH website which is the scientific face of the SCORCH program. Background Single Nucleus Assays: Molecular analysis of brain tissue typically relies on ensemble averaging of heterogenous mixtures of cell types within a specific brain region. However, technological advances enable molecular characterization of large numbers of individual cells. Single cell approaches can uncover effects on rarer cell types and have the potential to reveal cellular differences resulting from specific niche environments or transitory cellular states. Some single cell technologies in use include single cell RNA-sequencing (scRNA-seq), single nucleus RNA-sequencing (snRNA-seq), single nucleus assay for transposase-accessible chromatin-sequencing (snATAC-seq), single cell Hi-C, and spatial genomics approaches such as multiplexed fluorescence in situ hybridization (FISH). Individual researchers as well as large project teams including the Human Cell Atlas, Common Fund Human BioMolecular Atlas Program (HuBMAP), and NIH BRAIN Initiative Cell Atlas Network (BICAN) are exploiting these technologies to understand the diversity of cell types within the human body as well as their functions in human health and disease. Addictive Substances. Chronic exposure to addictive substances can lead to long term changes in brain function and to substance use disorders (SUDs). Many known brain regions are involved in addictive processes including the prefrontal cortex, nucleus accumbens, ventral tegmental area, striatum, insula, amygdala, and hippocampus. Despite great advances in our understanding of molecular pathways and circuits involved in SUDs, there remains limited knowledge concerning 1. The specific types, numbers, and gene expression profiles of cells within these brain regions and 2. How exposures to addictive substances influence the states and functions of these cells. HIV/ART. Antiretroviral therapy (ART) has, in large part, transformed the HIV epidemic into a chronic manageable disease in the United States. However, people living with HIV remain at higher risk for impaired cognitive functions (e.g. HIV-Associated Neurocognitive Disorder [HAND]). Use of addictive substances by HIV-infected individuals has the potential to further alter immune function and/or exacerbate HIV-related CNS impairment. However, little is known about 1. The effects of persistent HIV infection or HIV treatment regimens on gene expression in specific CNS cell types in key brain regions, or 2. How chronic addictive substance use might modify these effects. SCORCH. The Single Cell Opioid Responses in the Context of HIV (SCORCH) consortium was formed to begin to address scientific questions about addiction and HIV/ART questions at the single cell level. Fifteen funded SCORCH data generation projects (NIDA SCORCH Program) have been generating brain snRNA-seq or snATAC-seq data. Four brain types are being assayed by all groups: control, drug-exposed/SUD, HIV+, and HIV+drug exposed/SUD. Emphasis is on individuals with chronic exposure to opioids, cocaine, methamphetamine, or cannabinoids. Four groups are generating data from non-human primate brain, four from rodent brain, and nine from human post-mortem brain with some data from human organoids as well. The SCORCH data coordination, analysis, and scientific outreach center was established to standardize and share the single cell molecular HIV/SUD data generated by this program by ensuring that the data is FAIR (Findable, Accessible, Interoperable, and Reusable). Harmonized molecular and single cell HIV/SUD data sets will enable data mining by the scientific community to uncover new HIV and/or SUD mechanisms and to identify candidate pathways for therapeutic intervention. The SCORCH Data Center will also enable future mining of these data sets as improved data science and information technology approaches are developed, maximizing NIDA ’s original investment in the data generating activities. Scope. The proposed project should be framed to answer one or more vexing questions about persistent HIV infection in the brain. In addition, the major thrust of the proposed project MUST: Propose to coordinate and analyze single cell and other molecular data sets generated by SCORCH and other NIDA-funded HIV and substance use disorder projects. Propose to make this data findable, accessible, interoperable, and reusable (FAIR) to enable secondary analyses by the scientific community. Applicants are encouraged to contact NIDA program staff to answer any questions. Key activities of the SCORCH Data Center will be to: Work with SCORCH consortium members to ensure that all data and metadata have standardized formats and associated quality metrics and have been processed through standardized pipelines. Associate new SCORCH data with clinical metadata from the appropriate brain banks or tissue sources. Work closely with the SCORCH consortium PD(s)/PI(s) to analyze the data generated, to develop analysis strategies to integrate the datasets in synergistic ways with other relevant datasets, and to share useful information and insights about these data with the broader biomedical research community. It is anticipated that the SCORCH Data Center will lead an integrative analysis of all the SCORCH single cell data in a capstone publication. Develop strategies to enable and improve coordination, analysis, and sharing of spatial genomics and related data types. Develop strategies to enable and improve coordination, analysis, and sharing of data types from spatially and/or functionally resolved cellular assemblies relevant to HIV or addiction. Examples include but are not limited to anatomical structures, functional networks and ensembles characterized under PAR-20-241/ RFA-DA-22-011/ RFA-DA-23-035 “Large Scale Integrated Mapping and Molecular Profiling of Cell Ensembles and/or Cell-Types Mediating Opioid Action in the Rodent Brain” and RFA-DA-23-036 “Investigating the Effects of Addictive Substances on Brain Developmental Trajectories Using Innovative Scalable Methods for Quantification of Cell Identity, Lineage and Connectivity.” Archive raw and processed datasets generated by the SCORCH consortium in appropriate NIH-supported archives. Maintain, and improve a website to serve as a community-wide nexus for SCORCH protocols, assay and data standards, raw and processed data, data pipelines, and other resources generated by the consortium. Facilitate SCORCH data use by the scientific community for data mining to identify candidates for SUD and/or HIV therapeutic targets or to investigate SUD or HIV mechanisms. Provide user-friendly access to consortium data and by identifying or generating robust tools to enable both naive and experienced investigators to query, integrate, analyze, and model the data. Develop workshops and implement a community outreach strategy to inform the research community of the accomplishments of the SCORCH program and disseminate information about the community resources and data generated by the program. Coordinate SCORCH consortium activities by organizing steering committee meetings, workgroup meetings, external program consultant logistics, and other awardee meetings as needed. Plan for Enhancing Diverse Perspectives : This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP) as described in NOT-MH-21-310, submitted as Other Project Information as an attachment (see Section IV). Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. The PEDP will be assessed as part of the scientific and technical peer review evaluation, as well as considered among programmatic matters with respect to funding decisions.

This funding opportunity provides financial support for researchers and institutions to discover and develop new treatments for serious fungal infections that are difficult to treat due to resistance and safety issues.

The IDEA Fund program is a state-sponsored venture capital initiative that utilizes public funding (both state and federal) to drive economic development within the state. The primary focus of this program is to foster innovation and support technology-driven entrepreneurial endeavors that contribute to the state’s overall economic development growth. MTC’s Venture Capital Program was created to accelerate private venture capital investment in Missouri-based start-up companies and to increase the overall investment impact of third-party investments. The Venture Capital Program supports technology startups through matching equity or convertible debt investments up to $2,000,000 for the purpose of scaling the business to attract additional venture capital. Since 2010, MTC has invested over $49 million in more than 150 early-stage Missouri-based high-growth technology-focused companies. Since 2018, our portfolio companies have gone on to raise over $1.6 billion in additional private capital.

This funding opportunity provides financial support to Massachusetts-based organizations that help early-stage climatetech startups grow and innovate, covering various operational and developmental expenses.

This grant provides funding to U.S. nurse researchers and institutions to develop resources and support innovative studies focused on preventing firearm injuries, particularly among marginalized populations.

This funding opportunity supports postdoctoral researchers with clinical doctorate degrees in transitioning to independent faculty positions while leading their own clinical trials in biomedical research.